目的观察理冲生髓饮有效组分(LCSSY)调控腺苷酸活化蛋白激酶(AMPK)/哺乳动物雷帕霉素靶蛋白(mTOR)/丝氨酸苏氨酸蛋白激酶-失调51样激酶1(ULK1)信号通路对卵巢癌自噬的影响。方法体外培养卵巢癌SKOV3细胞,制备LCSSY含药血清,采用随机数...目的观察理冲生髓饮有效组分(LCSSY)调控腺苷酸活化蛋白激酶(AMPK)/哺乳动物雷帕霉素靶蛋白(mTOR)/丝氨酸苏氨酸蛋白激酶-失调51样激酶1(ULK1)信号通路对卵巢癌自噬的影响。方法体外培养卵巢癌SKOV3细胞,制备LCSSY含药血清,采用随机数字表法将SD大鼠分为空白对照组和LCSSY低、中、高剂量组。细胞计数盒8法检测卵巢癌SKOV3细胞增殖抑制率;蛋白质印迹法检测计算自噬相关蛋白重组人自噬效应蛋白(Beclin-1)、人微管相关蛋白轻链3Ⅱ与小鼠微管相关蛋白轻链3Ⅰ比值(LC3Ⅱ/Ⅰ)、自噬接头蛋白(P62)以及AMPK/mTOR/ULK1信号通路相关蛋白的表达,并采用AMPK激活剂验证其作用机制。结果给药24、48 h,LCSSY低、中、高剂量组对SKOV3细胞增殖的抑制率均大于空白对照组,且随着药物浓度的增加抑制程度逐渐加强(均P<0.05);另外,给药48 h LCSSY低剂量组、LCSSY中剂量组抑制率均大于本组给药24 h时(均P<0.05)。与空白对照组比较,LCSSY低、中、高剂量组均能够下调Beclin-1和LC3Ⅱ/Ⅰ的表达,上调P62的表达,且呈剂量依赖性[(0.98±0.02)、(0.59±0.02)、(0.55±0.02)比(1.46±0.12),(4.45±0.21)、(4.00±0.25)、(2.95±0.21)比(5.98±0.23),(0.67±0.02)、(0.94±0.05)、(1.53±0.13)比(0.30±0.02)](均P<0.05)。与空白对照组比较,LCSSY低、中、高剂量组均可以降低AMPK和ULK1表达,升高mTOR复合物1表达,且呈剂量依赖性(均P<0.05)。AMPK激活剂逆转AMPK/mTOR/ULK1信号通路后,与单独LCSSY高剂量组相比,LCSSY高剂量联合AMPK激活剂组使AMPK、ULK1蛋白表达量升高,而mTOR复合物1蛋白表达量降低(均P<0.05)。结论LCSSY可能通过调控AMPK/mTOR/ULK1信号通路抑制卵巢癌细胞自噬。展开更多
睡眠障碍是围绝经期女性常见症状之一,临床表现为入睡困难,夜间觉醒次数增多,睡眠质量下降等。非药物疗法治疗围绝经期睡眠障碍的方法有针灸、穴位贴敷、穴位埋线等中医外治法、心理疗法、运动疗法等,上述疗法治疗围绝经期睡眠障碍的疗...睡眠障碍是围绝经期女性常见症状之一,临床表现为入睡困难,夜间觉醒次数增多,睡眠质量下降等。非药物疗法治疗围绝经期睡眠障碍的方法有针灸、穴位贴敷、穴位埋线等中医外治法、心理疗法、运动疗法等,上述疗法治疗围绝经期睡眠障碍的疗效较为明确。其中中医外治法可单独或与药物等常规方法联合应用,具有整体调节的特色诊疗优势,心理疗法对医师专业技能要求较高。目前关于非药物疗法围绝经期睡眠障碍的研究多以观察临床疗效为主,少见作用机制探讨及大样本临床研究,相关疗法临床操作规范化也有待进一步研究。Sleep disorder is one of the common symptoms of perimenopause women, which is clinically manifested as difficulty in falling sleep, increasing number of night awakneings, and decreasing sleep quality. Non-drug therapy for perimenopausal sleep disorders include acupuncture and moxibustion, acupoint application, acupoint embedding and other external treatment of traditional Chinese medicine, psychotherapy, exercise therapy, etc. The therapeutic effect of the above therapy for perimenopausal sleep disorders is relatively clear. The external treatment of traditional Chinese medicine can be applied alone or in combination with convetional methods such as drugs, which has the characteristics of diagnosis and treatment advantages of overall regulation. Psychological therapy requires high professional skills of physicians. At present, the research on non-drug therapy for perimenopausal sleep disorders mainly focuses on the observation of clinical efficacy, and rarely discusses the mechanism of action and large-scale clinical studies. The standardization of clinical operation of related therapies also needs further research.展开更多
盆腔炎性疾病(PID)是育龄期女性的常见病和多发病,其发病率逐年呈上升趋势。临床上西药治疗有一定的局限性,对没有确定病原体的PID治疗效果不尽如人意,且长期使用抗生素会产生耐药菌,并使双重感染的风险大幅增加。然而,抑制疾病进展和缓...盆腔炎性疾病(PID)是育龄期女性的常见病和多发病,其发病率逐年呈上升趋势。临床上西药治疗有一定的局限性,对没有确定病原体的PID治疗效果不尽如人意,且长期使用抗生素会产生耐药菌,并使双重感染的风险大幅增加。然而,抑制疾病进展和缓解PID长期后遗症的新药需求尚未得到满足,中医药治疗因其副作用少,且治疗慢性病疗效明显而受到广泛关注。近年来,中医药在PID的治疗方面取得了明显进展,而中药单体是中草药中的活性成分,是新药开发的重要来源,为综述中药单体治疗PID的作用机制,本文总结了白芍总苷、金刚藤多糖、白藜芦醇、丹皮酚、连翘提取物、白头翁皂苷B4、菝葜总黄酮、芹菜素、菊苣酸、淫羊藿苷、柴胡皂苷A等在PID治疗过程中的关键环节,以期为临床PID的防治及新药研发提供参考依据和研究方向。Pelvic inflammatory disease (PID) is a common and frequent disease in women of reproductive age, and its incidence is on the rise year by year. Clinical treatment with western drugs has limitations and is unsatisfactory for the treatment of PID without identified pathogens, and the long-term use of antibiotics produces drug-resistant organisms and dramatically increases the risk of double infections. However, there is an unmet need for new drugs to inhibit disease progression and alleviate the long-term sequelae of PID, and TCM treatment has received widespread attention because of its few side effects and its efficacy in treating chronic diseases. In recent years, TCM has made significant progress in the treatment of PID, and TCM monomers, the active ingredients in TCM, are an important source of new drug development. To review the mechanism of action of TCM monomers in the treatment of PID, this paper summarizes the role of Total glucosides of paeonyia, Smilax china L. polysaccharides, resveratrol, paeonol, forsythia suspensa extract, anemoside B4, total flavones of Smilax china L., apigenin, chicoric acid, and icariin, saikosaponin A and other key links in the treatment process of PID, with a view to providing a reference basis and research direction for the prevention and treatment of clinical PID and the development of new drugs.展开更多
文摘目的观察理冲生髓饮有效组分(LCSSY)调控腺苷酸活化蛋白激酶(AMPK)/哺乳动物雷帕霉素靶蛋白(mTOR)/丝氨酸苏氨酸蛋白激酶-失调51样激酶1(ULK1)信号通路对卵巢癌自噬的影响。方法体外培养卵巢癌SKOV3细胞,制备LCSSY含药血清,采用随机数字表法将SD大鼠分为空白对照组和LCSSY低、中、高剂量组。细胞计数盒8法检测卵巢癌SKOV3细胞增殖抑制率;蛋白质印迹法检测计算自噬相关蛋白重组人自噬效应蛋白(Beclin-1)、人微管相关蛋白轻链3Ⅱ与小鼠微管相关蛋白轻链3Ⅰ比值(LC3Ⅱ/Ⅰ)、自噬接头蛋白(P62)以及AMPK/mTOR/ULK1信号通路相关蛋白的表达,并采用AMPK激活剂验证其作用机制。结果给药24、48 h,LCSSY低、中、高剂量组对SKOV3细胞增殖的抑制率均大于空白对照组,且随着药物浓度的增加抑制程度逐渐加强(均P<0.05);另外,给药48 h LCSSY低剂量组、LCSSY中剂量组抑制率均大于本组给药24 h时(均P<0.05)。与空白对照组比较,LCSSY低、中、高剂量组均能够下调Beclin-1和LC3Ⅱ/Ⅰ的表达,上调P62的表达,且呈剂量依赖性[(0.98±0.02)、(0.59±0.02)、(0.55±0.02)比(1.46±0.12),(4.45±0.21)、(4.00±0.25)、(2.95±0.21)比(5.98±0.23),(0.67±0.02)、(0.94±0.05)、(1.53±0.13)比(0.30±0.02)](均P<0.05)。与空白对照组比较,LCSSY低、中、高剂量组均可以降低AMPK和ULK1表达,升高mTOR复合物1表达,且呈剂量依赖性(均P<0.05)。AMPK激活剂逆转AMPK/mTOR/ULK1信号通路后,与单独LCSSY高剂量组相比,LCSSY高剂量联合AMPK激活剂组使AMPK、ULK1蛋白表达量升高,而mTOR复合物1蛋白表达量降低(均P<0.05)。结论LCSSY可能通过调控AMPK/mTOR/ULK1信号通路抑制卵巢癌细胞自噬。
文摘睡眠障碍是围绝经期女性常见症状之一,临床表现为入睡困难,夜间觉醒次数增多,睡眠质量下降等。非药物疗法治疗围绝经期睡眠障碍的方法有针灸、穴位贴敷、穴位埋线等中医外治法、心理疗法、运动疗法等,上述疗法治疗围绝经期睡眠障碍的疗效较为明确。其中中医外治法可单独或与药物等常规方法联合应用,具有整体调节的特色诊疗优势,心理疗法对医师专业技能要求较高。目前关于非药物疗法围绝经期睡眠障碍的研究多以观察临床疗效为主,少见作用机制探讨及大样本临床研究,相关疗法临床操作规范化也有待进一步研究。Sleep disorder is one of the common symptoms of perimenopause women, which is clinically manifested as difficulty in falling sleep, increasing number of night awakneings, and decreasing sleep quality. Non-drug therapy for perimenopausal sleep disorders include acupuncture and moxibustion, acupoint application, acupoint embedding and other external treatment of traditional Chinese medicine, psychotherapy, exercise therapy, etc. The therapeutic effect of the above therapy for perimenopausal sleep disorders is relatively clear. The external treatment of traditional Chinese medicine can be applied alone or in combination with convetional methods such as drugs, which has the characteristics of diagnosis and treatment advantages of overall regulation. Psychological therapy requires high professional skills of physicians. At present, the research on non-drug therapy for perimenopausal sleep disorders mainly focuses on the observation of clinical efficacy, and rarely discusses the mechanism of action and large-scale clinical studies. The standardization of clinical operation of related therapies also needs further research.
文摘盆腔炎性疾病(PID)是育龄期女性的常见病和多发病,其发病率逐年呈上升趋势。临床上西药治疗有一定的局限性,对没有确定病原体的PID治疗效果不尽如人意,且长期使用抗生素会产生耐药菌,并使双重感染的风险大幅增加。然而,抑制疾病进展和缓解PID长期后遗症的新药需求尚未得到满足,中医药治疗因其副作用少,且治疗慢性病疗效明显而受到广泛关注。近年来,中医药在PID的治疗方面取得了明显进展,而中药单体是中草药中的活性成分,是新药开发的重要来源,为综述中药单体治疗PID的作用机制,本文总结了白芍总苷、金刚藤多糖、白藜芦醇、丹皮酚、连翘提取物、白头翁皂苷B4、菝葜总黄酮、芹菜素、菊苣酸、淫羊藿苷、柴胡皂苷A等在PID治疗过程中的关键环节,以期为临床PID的防治及新药研发提供参考依据和研究方向。Pelvic inflammatory disease (PID) is a common and frequent disease in women of reproductive age, and its incidence is on the rise year by year. Clinical treatment with western drugs has limitations and is unsatisfactory for the treatment of PID without identified pathogens, and the long-term use of antibiotics produces drug-resistant organisms and dramatically increases the risk of double infections. However, there is an unmet need for new drugs to inhibit disease progression and alleviate the long-term sequelae of PID, and TCM treatment has received widespread attention because of its few side effects and its efficacy in treating chronic diseases. In recent years, TCM has made significant progress in the treatment of PID, and TCM monomers, the active ingredients in TCM, are an important source of new drug development. To review the mechanism of action of TCM monomers in the treatment of PID, this paper summarizes the role of Total glucosides of paeonyia, Smilax china L. polysaccharides, resveratrol, paeonol, forsythia suspensa extract, anemoside B4, total flavones of Smilax china L., apigenin, chicoric acid, and icariin, saikosaponin A and other key links in the treatment process of PID, with a view to providing a reference basis and research direction for the prevention and treatment of clinical PID and the development of new drugs.